Paisalo Digital Q1 results: Revenue rises 17% YoY to Rs 218.7 crore, Net profit up 14% YoY
For Q1 FY26, the company's consolidated net profit increased 14% year-on-year (YoY) to ₹47.2 crore, compared to ₹41.5 crore in Q1 FY25. The company also reported a robust 17% YoY rise in total income to ₹218.7 crore, up from ₹186.6 crore last year. Net Interest Income (NII) rose by 20% YoY to ₹124.4 crore, from ₹103.5 crore in Q1 FY25.
The company's Assets Under Management (AUM) stood at ₹5,230.2 crore, marking a 14% increase YoY. Disbursements grew 16% YoY to ₹758.1 crore during the quarter.
In terms of asset quality, Paisalo Digital maintained healthy levels with Gross Stage 3 (GNPA) at 0.85% and Net Stage 3 (NNPA) at 0.68%, albeit slightly higher than the previous year. The collection efficiency remained high at 99.8%, underscoring the company's robust credit practices.
Operational highlights: Return on Assets (RoA): 3.7% vs 4.0% YoY
Return on Equity (RoE): 11.9% vs 12.0% YoY
Net Worth: ₹1,574.6 crore, up 15% YoY
Capital Adequacy Ratio: 39.5% (Tier 1: 30.4%)
During the quarter, the company added approximately 1.5 million customers, bringing the total customer base to ~11 million, and expanded its footprint to 3,997 touchpoints across 22 states with 401 branches. It also extended its co-lending partnership with SBI to jointly fund MSME and SME loans, strengthening its inclusive growth initiatives.
Deputy MD Santanu Agarwal commented, 'Q1 FY26 marks a good start to the year as we delivered our highest-ever total income and added 1.5 million customers in a single quarter. We remain focused on scaling responsibly, innovating continuously, and empowering millions more in the quarters ahead.'
The company will host an earnings call on July 22, 2025, at 4:00 PM IST to discuss the results in detail.
Disclaimer: The information provided is for informational purposes only and should not be construed as financial or investment advice. Stock market investments are subject to market risks. Please consult a financial advisor or conduct your own research before making any investment decisions.
Ahmedabad Plane Crash
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
3 hours ago
- Business Upturn
Indoco Remedies gets USFDA nod for generic Rivaroxaban tablets; eyes growth in US Market
Mumbai-based Indoco Remedies Ltd. has secured final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) to market Rivaroxaban Tablets USP in strengths of 2.5 mg, 10 mg, 15 mg, and 20 mg. The product is the generic equivalent of Janssen Pharmaceuticals' blockbuster anticoagulant, Xarelto, and will be manufactured at Indoco's Verna, Goa facility. The approved Rivaroxaban tablets are bioequivalent and therapeutically equivalent to Xarelto and are indicated for the treatment of venous thromboembolism (VTE). This approval marks another milestone in Indoco's push into the US generics market, one of the most lucrative pharmaceutical markets globally. Commenting on the development, Indoco Remedies' Managing Director Aditi Panandikar said, 'Besides reflecting the capability of Indoco Remedies to deliver products of high-quality standards, this development also provides impetus to our growth aspirations in an important market such as the US.' Indoco Remedies is a fully integrated, research-driven pharmaceutical company with a global footprint, generating over 106 million prescriptions annually in India alone. The company operates 11 manufacturing facilities — seven for finished dosage forms (FDFs) and four for active pharmaceutical ingredients (APIs) — all of which are approved by top global regulatory agencies including the USFDA and UK-MHRA. With a turnover of $180 million and a workforce of more than 6,000 employees, Indoco is known for popular domestic brands such as Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, and Cital. Internationally, the company partners with large generics players to expand its market reach across multiple geographies. The latest USFDA approval strengthens Indoco's product portfolio in the regulated market and could open up significant revenue opportunities as Rivaroxaban continues to be a widely prescribed oral anticoagulant in the US. Disclaimer: This news article is for informational purposes only and does not constitute investment advice. Investors should consult a qualified financial advisor before making investment decisions. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
3 hours ago
- Business Upturn
Why are Indoco Remedies shares up 2% today? Explained
By Aditya Bhagchandani Published on August 13, 2025, 10:05 IST Indoco Remedies Ltd shares climbed over 2% to ₹299.30 in morning trade on Tuesday after the company announced it has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Rivaroxaban tablets, a generic version of Bayer's blockbuster anticoagulant Xarelto. The approval covers multiple dosage strengths — 2.5 mg, 10 mg, 15 mg, and 20 mg — positioning Indoco to tap into the lucrative US market for blood thinners, which has significant demand due to rising cardiovascular cases. Industry data shows Rivaroxaban sales in the US crossed $2 billion in recent years. Indoco said the launch will be executed through its marketing partner in the US, adding that this development strengthens its complex generics portfolio and enhances its revenue visibility in the American market. The stock's rally reflects investor optimism about the earnings potential from this launch, given that US generics typically offer higher margins than domestic formulations. Disclaimer: This article is for informational purposes only and does not constitute financial advice. Investing in equities involves risks. Please consult a certified financial advisor before making any investment decisions. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
4 hours ago
- Business Upturn
NHPC shares edge up 2% after Q1 profit rises 3% on higher income
By Aditya Bhagchandani Published on August 13, 2025, 09:55 IST NHPC Ltd shares rose nearly 2% in early trade on Wednesday, August 13, after the state-owned hydropower major reported a modest rise in its June quarter earnings, backed by higher income and fresh capacity additions. The stock opened firm at ₹83.91 and climbed to ₹85.86 during the session, trading at ₹85.56, up 1.97%, with a market cap of ₹858.35 crore. Q1 FY26 Earnings Snapshot For the quarter ended June 30, 2025, NHPC posted a net profit of ₹1,131.16 crore, up 3% from ₹1,101.63 crore in the same quarter last year. The increase was driven by a 13% jump in total income to ₹3,442.76 crore, compared with ₹3,037.92 crore a year earlier. The state-run utility also commissioned the 800 MW Parbati-II Project during the quarter, further expanding its operational capacity. Additionally, it brought online 214.28 MW out of the 300 MW Kamisar Solar Power Project in Bikaner, reflecting its growing footprint in renewable energy beyond hydro. Operational Highlights Hydropower Focus: NHPC continues to be India's largest hydropower development organisation under the Ministry of Power, with capabilities spanning conception to commissioning of hydro projects. Renewables Expansion: The company is steadily diversifying into solar and wind energy, complementing its hydro portfolio. Strategic Additions: Capacity expansions this quarter align with the government's renewable push and NHPC's long-term growth strategy. Market Reaction Investor sentiment was buoyed by the revenue growth and commissioning of new projects, although the profit growth remained modest. Analysts see NHPC's expansion into solar as a positive long-term catalyst, but the near-term earnings trajectory will depend on seasonal power demand and execution timelines for under-construction projects. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
